Logo
x

Search

Subscribe Now

Follicular Lymphoma

Novartis Presents Results of Kymriah in P-II ELARA Study for Relapsed or Refractory Follicular Lymphoma at ASCO 2021

Novartis Presents Results of Kymriah in P-II ELARA Study for Relapsed or Refractory Follicular Lymphoma at ASCO 2021

  • June 3, 2021
Kite's Yescarta Receives the US FDA's Approval for R/R Follicular Lymphoma

Kite's Yescarta Receives the US FDA's Approval for R/R Follicular Lymphoma

  • March 8, 2021
BioInvent Presents New Clinical and Preclinical Data of BI-1206 at ASH Annual Meeting

BioInvent Presents New Clinical and Preclinical Data of BI-1206 at ASH Annual Meeting

  • November 5, 2020
Novartis Reports Results of Kymriah (tisagenlecleucel) in P-II ELARA Study for Follicular Lymphoma

Novartis Reports Results of Kymriah (tisagenlecleucel) in P-II ELARA Study for Follicular Lymphoma

  • August 4, 2020
Roche's Mosunetuzumab Receives the US FDA's Breakthrough Therapy Designation to Treat Relapsed or Refractory Follicular Lymphoma

Roche's Mosunetuzumab Receives the US FDA's Breakthrough Therapy Designation to Treat Relapsed or Refractory Follicular Lymphoma

  • July 14, 2020
Novartis' Kymriah (tisagenlecleucel) Receives the US FDA's Regenerative Medicine Advanced Therapy Designation for Follicular Lymphoma

Novartis' Kymriah (tisagenlecleucel) Receives the US FDA's Regenerative Medicine Advanced Therapy Designation for Follicular Lymph...

  • April 22, 2020
Incyte Reports Topline Data from P-III (inMIND) Trial of Monjuvi to Treat Relapsed or Refractory FL

    Incyte Reports Topline Data from P-III (inMIND) Trial of Monjuvi to Treat Relapsed or Refractory FL

    • August 16, 2024
    HUTCHMED Reports the NMPA’s NDA Acceptance of Tazemetostat for Treating Follicular Lymphoma

      HUTCHMED Reports the NMPA’s NDA Acceptance of Tazemetostat for Treating Follicular Lymphoma

      • July 4, 2024
      AbbVie’s Tepkinly (Epcoritamab) Gains the CHMP’s Positive Opinion to Treat R/R Follicular Lymphoma

        AbbVie’s Tepkinly (Epcoritamab) Gains the CHMP’s Positive Opinion to Treat R/R Follicular Lymphoma

        • July 1, 2024
        Regeneron’s Ordspono Gains the CHMP’s Positive Opinion to Treat r/r Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)

          Regeneron’s Ordspono Gains the CHMP’s Positive Opinion to Treat r/r Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLB...

          • June 28, 2024
          AbbVie’s Epkinly (epcoritamab-bysp) Receives the US FDA’s Accelerated Approval to Treat R/R Follicular Lymphoma

            AbbVie’s Epkinly (epcoritamab-bysp) Receives the US FDA’s Accelerated Approval to Treat R/R Follicular Lymphoma

            • June 27, 2024
            BMS Highlights Data from three P-III Studies of Breyanzi to Treat Various B-Cell Malignancies at ASCO 2024

              BMS Highlights Data from three P-III Studies of Breyanzi to Treat Various B-Cell Malignancies at ASCO 2024

              • June 4, 2024
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.